Table 2.
Univariate and Multivariate Survival Analyses of Breast CSS in Cohorts I and II
| Variable | No. | Multivariate Adjusted (Weibull) |
Unadjusted (Weibull) |
||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Cohort I (CSS)* | |||||||
| Tumor grade | |||||||
| 1 | 47 | 1 | — | 1 | — | ||
| 2 | 76 | 1.53 | 0.57 to 4.10 | .399 | 1.87 | 0.72 to 4.87 | .198 |
| 3 | 60 | 1.61 | 0.56 to 4.66 | .381 | 2.74 | 1.05 to 7.11 | .039 |
| Tumor size, cm | |||||||
| < 2 | 88 | 1 | — | 1 | — | ||
| ≥ 2-< 5 | 87 | 2.30 | 1.06 to 4.99 | .036 | 2.47 | 1.20 to 5.08 | .014 |
| ≥ 5 | 8 | 2.50 | 0.62 to 10.04 | .197 | 2.97 | 0.80 to 10.95 | .103 |
| ER status | |||||||
| Negative | 32 | 1 | — | 1 | — | ||
| Positive | 151 | 1.82 | 0.70 to 4.71 | .216 | 0.72 | 0.34 to 1.51 | .380 |
| PR status | |||||||
| Negative | 64 | 1 | — | 1 | — | ||
| Positive | 119 | 0.55 | 0.25 to 1.20 | .133 | 0.55 | 0.29 to 1.04 | .065 |
| Nuc-pYStat5 | |||||||
| Low (0) | 105 | 2.38 | 1.13 to 5.04 | .023 | 2.32 | 1.10 to 4.89 | .027 |
| High (> 0) | 78 | 1 | — | 1 | — | ||
| Cohort II (CSS)† | |||||||
| Tumor grade | |||||||
| 1 | 34 | 1 | — | 1 | — | ||
| 2 | 90 | 1.25 | 0.66 to 2.37 | .500 | 1.16 | 0.62 to 2.19 | .640 |
| 3 | 34 | 0.87 | 0.35 to 2.19 | .772 | 0.81 | 0.36 to 1.82 | .616 |
| Tumor size, cm | |||||||
| < 2 | 60 | 1 | — | 1 | — | ||
| ≥ 2-< 5 | 80 | 2.49 | 1.33 to 4.67 | .004 | 2.11 | 1.15 to 3.88 | .016 |
| ≥ 5 | 18 | 3.89 | 1.63 to 9.26 | .002 | 2.68 | 1.19 to 6.05 | .018 |
| ER status | |||||||
| Negative | 50 | 1 | — | 1 | — | ||
| Positive | 108 | 0.88 | 0.45 to 1.70 | .698 | 1.01 | 0.59 to 1.73 | .958 |
| PR status | |||||||
| Negative | 57 | 1 | — | 1 | — | ||
| Positive | 101 | 1.26 | 0.69 to 2.29 | .459 | 0.92 | 0.55 to 1.55 | .757 |
| HER2 status | |||||||
| Normal | 138 | 1 | — | 1 | — | ||
| Overexpressed | 20 | 1.37 | 0.61 to 3.07 | .440 | 1.04 | 0.49 to 2.19 | .918 |
| Nuc-pYStat5 | |||||||
| Low (< 684) | 67 | 2.39 | 1.37 to 4.17 | .002 | 2.10 | 1.26 to 3.51 | .004 |
| High (≥ 684) | 91 | 1 | — | 1 | — | ||
NOTE. Weibull regression survival analysis was used to evaluate prognostic factors. Global test for Cox regression proportional hazards assumption failed, necessitating Weibull regression. Cohort I: n = 233; 183 (79%) evaluable; 41 (22%) of 183 events. Cohort II: n = 291; 158 (54%) evaluable; 61 (39%) of 158 events.
Abbreviations: CSS, cancer specific survival; HR, hazard ratio; ER, estrogen receptor; PR, progesterone receptor; Nuc-pYStat5, nuclear localized and tyrosine phosphorylated Stat5.
*
Global test: χ2(5) = 12.93, P = .024.
†
Global test: χ2(6) = 13.22, P = .040.